CryoLife, Inc. Q2 2008 Financial Summary
Business Context and Reporting Period
This summary covers CryoLife, Inc.'s (the "Company") Form 10-Q for the quarterly period ended June 30, 2008. CryoLife develops and commercializes biomaterials and implantable medical devices (notably BioGlue) and preserves/distributes human tissues for cardiac and vascular transplant applications. The Company operates two primary segments: Preservation Services and Implantable Medical Devices.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2008 | Six Months Ended June 30, 2008 |
|---|---|---|
| Total Revenues | $27.2 million | $52.7 million |
| Net Income | $3.9 million | $6.7 million |
| Diluted EPS | $0.14 | $0.24 |
| Operating Cash Flow (6mo) | $2.8 million | |
| Cash & Equivalents (End of Period) | $11.7 million | |
| Debt (Line of Credit) | $0.3 million outstanding (of $15.0m facility) | |
| Current Ratio | 3.15 to 1 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 18% year-over-year (Q2) and 11% (YTD). Growth was driven by BioGlue sales (+19% Q2) and preservation services (+17% Q2).
- Profitability: Net income surged 201% in Q2 and 152% YTD compared to 2007. This improvement is largely due to the absence of a $0.9 million derivative valuation expense recorded in Q2 2007 related to preferred stock conversion.
- Segment Performance:
- Cardiac Services: Revenues up 26% due to volume increases and the introduction of the premium CryoValve SG.
- Vascular Services: Revenues up 30% driven by a 26% increase in unit shipments of saphenous veins.
- Orthopaedic Services: Revenues declined 76% as the Company ceased marketing these services per an agreement with Regeneration Technologies, Inc. (RTI).
- Cost Structure: Cost of preservation services as a percentage of revenue improved to 54% (from 60% in 2007) due to higher service fees and the absence of inventory write-downs recorded in the prior year.
Outlook, Risks, and Contingencies
- Product Liability: The Company accrued $5.0 million for unreported product liability claims as of June 30, 2008, with an estimated insurance recovery of $1.6 million. Actuarial analysis suggests the liability could range up to $10.0 million. One pending lawsuit regarding orthopaedic tissue is in the discovery stage.
- Deferred Tax Assets: The Company maintains a full valuation allowance ($28.2 million) against deferred tax assets. Management believes it is "more likely than not" that these assets will not be realized, though a reversal could occur if profitable operations continue, which would significantly impact future effective tax rates.
- Liquidity & Debt: The Company entered a new $15.0 million credit facility with GE Capital in March 2008. Covenants require maintaining $5.0 million in restricted cash, which is classified as a long-term asset. The Company believes current resources are sufficient for the next 12 months.
- Strategic Initiatives: The Company is pursuing acquisitions, technology licensing, and asset disposals. It recently signed an exclusive distribution agreement for Hemostase MPH and received CE Mark approval for BioGlue in brow lift procedures.
Investor Verification Checklist
- Verify the assumptions and potential volatility in the $5.0 million product liability accrual and the adequacy of insurance coverage.
- Monitor the valuation allowance on deferred tax assets for potential reversal, which would alter future tax expense and net income.
- Assess the sustainability of CryoValve SG premium pricing and shipment volumes as a driver of cardiac segment growth.
- Review compliance with GE Capital credit covenants, specifically the Adjusted EBITDA requirements and restricted cash maintenance.
- Track the commercialization progress of new products like Hemostase MPH and the impact of the RTI agreement on orthopaedic revenue decline.